Press Releases

--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in
Read More
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical study in first
Read More
Displaying 1 - 10 of 25
Print Page
Email Alerts
RSS
Investor Contact
Search